Bayer makes hot flash splash, hitting phase 3 breast cancer goal to steal march on Astellas

Bayer’s hot flash drug candidate has hit the mark in a phase 3 breast cancer trial, potentially positioning the German drugmaker to get the jump on Astellas’ rival drug Veozah.